יתרון מוטל בספק למתן תרופות מרשם למטופלים בטרם מוות: מחקר רטרוספקטיבי על מטופלי בתי אבות עם ובלי דמנציה בגרמניה
Subscribe to Medic
The only Israeli drug index for medical professionals
Search all the drugs distributed in Israel
CCB, Local Anesthetic. Lidocaine HCl 1.5%, Nifedipine 0.3%. RECTAL CR.: 30g. Should be applied twice dly. for at least 3 wks. See lit.
Tmt. of anal fissures and proctolog. general. associate. with anal sphincter hypertonia.
C/I: Hypersens. to the active ingred., partic. to Lidocaine (& other local anesthet. with a similar amidic type structure). Presumed or ascertained preg. & lact.
Urinary Tract Analgesic. Phenazopyridine (as HCl) 100 mg. TABS: 30. Adult and children over 12
years: 2 drugs. 3 x dly. Aft. meals.
Children from 6 to 12 years: 12mg/kg
bdy wt divided into 3 daily doses.
Relief pain, burning, urgency.
C/I: G6PD deficiency, renal insuffic.
hepatic insuffic., hepatitis, hypersens.
Analgesic, Antipyretic, Opioid. Caffeine 50 mg, Codeine Phosphate 15 mg, Paracetamol 500 mg. CAPLETS: 12, 24. 1 capl. × 3-4 times/day. For severe pains - 2 capl. 3-4 times/day. Do not exceed a dosage of 8 capl. in 24 hrs. See lit.
For the relief of pain and coughs and for the reduction of fever accompanied by pain.
C/I: Hypersens. 1st & 3rd trim. of preg. Lact. Child. under 12 yrs. old. Adolesc. over 12 yrs. old and under 18 yrs. old after surg. remov. of their tonsils or adenoids. Concom. use with medic. contain. paracetamol /codeine. Pts. with respirat. depress. Pts. who are known as ultra-rapid metabolizer.
Amphetamines. Dextroamphetamine Saccharate 1.25, 2.5, 5, 7.5 mg, Amphetamine Aspartate Monohydrate 1.25, 2.5, 5, 7.5 mg, Dextroamphetamine Sulfate 1.25, 2.5, 5, 7.5 mg, Amphetamine Sulfate 1.25, 2.5, 5, 7.5 mg. TABS.: 100× 5, 10, 20, 30 mg. Not recom.
for child. under 3 yrs. of age. Child. 6
yrs. of age and older, start with 5 mg
once/twice dly.; daily dosage may be
inc. in increments of 5 mg at wkly.
intervals until optim. response is
obtained. Narcolepsy: Usual dose 5 mg
- 60 mg per day in divided doses,
depend. on the individ. pt. response.
Tmt. of ADHD and Narcolepsy.
C/I: Hypertens., hyperthyroid., known
hypersens./ idiosyncrasy to the
sympathomim. amines. Glaucoma.
Agitated states. Pts. with a hist.of drug
abuse. During or within 14 days follow.
the adminis. of MAO’s inhib. (hyperten.
crises may result). Advanced
arteriosclerosis, symptom. cardiovasc.
dis., moder.- sev.
Phosphate Binder. Sucroferric Oxyhydroxide 500 mg. CHEW. TABS.: 90. Init. dose 1,500 mg iron (3 tabs.)/d, divided across the meals of the day., must be taken with meals.
Pts. receiving should adhere to their prescribed diets.
Titrat.& mainten.: Serum phosphorus levels must be monit. and the dose up or down titrated in increm. of 500 mg iron (1 tab.)/d every 2-4 wks. until an accept. serum phosphorus level is reached, with regular monitor. afterwards.
In clinical practice, tmt. will be based on the need to control serum phosphorus levels, though pts. who respond to drug therapy usually achieve optimal serum phosphorus levels at doses of 1,500 mg-2,000 mg iron/d (3 - 4 tablets). See Lit.
Indicated for the control of serum phosphorus levels in adult chron. kidney dis. (CKD) pts. on haemodialys. (HD) or periton. dialys. (PD). The drug should be used within the context of a multiple therapeut. approach, which could include calcium supplem., 1,25-dihydroxy vitamin D3 or one of its analog., or calcimimetics to control the develop. of renal bone dis.
C/I: Hypersens. Haemochromatosis and any other iron accumulat. disord.
Antipsychotic. Zuclopenthixol 20 mg/ml. ORAL DROPS: 20 ml x 20 mg/ml (1 drop
= 1 mg). 20-30 mg dly. in div. doses.
Maint: 20-50 mg dly. Max: 150 mg dly.
Elderly: May have to reduce. Child: Not
Acute schizophrenia and other acute
C/I: As for other neuroleptics, intol. to
thioxanthenes. See lit.
Monoclonal Antibody. Trastuzumab 150, 420 mg. VIAL (Pwdr. for concentrate for sol. for infus.): 1. Dosage must be ajust. individ accord. pt. med. cond. and indication.
Tmt. of pts. with metast. breast canc. who have tumors that overexpress HER2;
As a single agent, for the tmt. of those pts. who have received one or more chemother. regim. for their metast. dis.
In comb. with Paclitaxel or Docetaxel for the tmt. of those pts. who have not received chemother. for their metast. dis.
In comb. with an aromatase inhib. for the tmt. of postmenopaus. pt. with hormonereceptor positive metast. breast canc.
Early breast cancer (EBC) – pts. with HER2 positive early breast cancer follow. surg. and chemother. (neoadjuv./ adjuvant) either alone or in comb. with chemother. exclude. anthracyclines.
The drug should only be used in pts. whose tumors have either HER2 overexpres. or HER2 gene amplificat. as determ. by an accurate and validated assay. HER2 Metastat. gast. cancer (MGC)- in comb. with capecitabine or 5-fluorouracil and cisplatin is indic. for the tmt. of pts. with HER2-positive metast. adenocarcinoma of the stomach or gastroesophag. junction who have not received prior anti-cancer tmt. for their metastat. dis.
Trastuzumab should only be used in pts. with metastat. gast. cancer (MGC) whose tumours have HER2 overexpres. as defined by IHC 2+ and a confirmatory FISH+ result, or IHC 3+, as determ. by an accurate and validated assay.
C/I: Hypersens. Severe dyspnea at rest due to complicat. of advanced malig. or require. supplement. oxygen ther.
(ADP-ribose) polymerase (PARP) inhibitor. Talazoparib Tosylate 0.25 mg, 1 mg. HARD CAPS.: 30×1 mg, 60×0.25 mg. 1 mg ×1/d taken orally, with/without food.
The 0.25 mg cap. is available for dose reduction.
Pts. should be treated until dis. progres. or unaccept. toxicity occurs.
To avoid contact with the caps. content, Talazoparib cap. should be swallow. whole, and must not be opened or dissolve.
If the pt. vomits or misses a dose, an addit. dose should not be taken. The next prescribed dose should be taken at the usual time.
Dose reduct. levels for adverse react. -See lit.
Tmt. of adult pts. with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epiderm. growth factor receptor 2 (HER2)-negative locally advanc. or metastat. breast cancer.
Drugs for treatment of hyperkalaemia and hyperphosphataemia. Patiromer 8.4 g, 16.8 g. SACHET. (Pwdr. for oral susp.): 30. The recommended init. dose is 8.4 g×1/d.
The dly. dose may be adjust. in intervals of 1 wk. or longer, based on the serum K+ level and the desired target range. The dly. dose may be incr. or decreas. by 8.4 g as necessary to reach the desired target range, up to a max. dose of 25.2 g dly.
If serum K+ falls below the desired range, the dose should be reduced or discont.
If a dose is missed, the missed dose should be taken as soon as possible on the same day. The missed dose should not be taken with the next dose.
Admin. be separated by 3 hrs. from other oral med. products.
The onset of action of Patiromer occurs 4-7 hrs. after admin. Patiromer should not replace emergency tmt. for life-threaten. hyperkalaem.
Treatment of hyperkalaemia in adults.